

# Oncolytic Virus Manufacturing

## Virus manufacturing for oncolytic therapies

ABL has increased capacity, increased scale, and diversified capabilities to offer a variety of suspension and adherent production platforms to manufacture our clients' novel oncolytic therapies.

### Global capabilities include:

- Oncolytic viral vector manufacturing – adherent & suspension platforms:
  - Vaccinia
  - MVA
  - HSV
  - Adenovirus
  - Others
- Aseptic processing for drug substance & drug product
- US- & EU-based GMP operations
- Global supply for Phase I – III & product approval
- Comprehensive QC release & stability testing
- Process & analytical development, qualification, characterization & validation
- 10+ years proven technical & regulatory track record in oncolytic virotherapies



## **ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France**

ABL, Inc. (ABL), a global contract manufacturing organization that advances leading vaccines and therapies from clinical development to the commercial market, is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m<sup>2</sup> GMP manufacturing site located in Lyon, France.

[Read More](#)  
[Go](#)

**Contact us now to speak with one of our experts:**

- Name\*

First

Last

- Company\*

- Email\*

- Phone\*

- Comments

Submit